ImmunityBio, Inc. (IBRX): debt financing — ImmunityBio secures $75M non-dilutive RIPA financing; $25M note conversion reduces debt

ImmunityBio, Inc.

Additional $75M under Revenue Interest Purchase Agreement (RIPA) with Oberland Capital; total committed capital $375M.
Royalty payback rate increased to tiered 5.625%-12.5% of net sales; cap at 195% of cumulative payments.
Proceeds to support global expansion, pipeline advancement, and general corporate purposes.
Nant Capital converted $25M of convertible note into 4,606,596 shares; note outstanding now $480M.
Recent ANKTIVA approvals in US, UK, EU, Saudi Arabia, Macau; covering ~34 countries.

item 1.01 item 2.03 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ImmunityBio, Inc. incurred debt of $75.0 million with Infinity SA LLC, as collateral agent and administrative agent for the Purchasers at tiered range of 5.625% to 12.50%.

Principal: $75.0 million
Counterparty: Infinity SA LLC, as collateral agent and administrative agent for the Purchasers
Rate: tiered range of 5.625% to 12.50%
Event: incurrence

Exact text from the filing

(the “Company”) entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”) by and among the Company, the guarantors party thereto, the purchasers party thereto (the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Agent”), which amends that certain Revenue Interest Purchase Agreement dated as of December 29, 2023, by and among the Company, the Purchasers and the Agent (as amended, modified and supplemented prior to the date of the Amendment, the “RIPA”).

View on SEC.gov

Browse all debt financings →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-133363

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.